Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P)

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 4, 2004, Pages 323-330

  Michiels, Jan Jacques ^a,b,c   Berneman, Zwi N ^a   Van Der Planken, Marc ^b   Schroyens, Wilfried ^a   Budde, Ulrich ^d   Van Vliet, Huub H D M ^e  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c Goodheart Institute   (Netherlands)

^d Coagulation Laboratory   (Germany)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bleeding time; DDAVP; Factor VIII vWF concentrates; Factor VIII:C; Haemate P; Ristocetin cofactor activity; Von Willebrand collagen binding activity; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLEEDING; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; EVALUATION; FEMALE; HUMAN; IN VIVO STUDY; MAJOR SURGERY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL PATIENT; TIME; TRANSFUSION; VON WILLEBRAND DISEASE;

ADULT; BLOOD LOSS, SURGICAL; BODY WEIGHT; DRUG COMBINATIONS; FACTOR VIII; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 2942557314     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200406000-00006     Document Type: Article

References (20)

1. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71:520-525.
2. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyenkov V, Ginsburg D, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84:160-174.
3. Michiels JJ, Van De Velde A, Van Vliet HHDM, Van Der Planken M, Schroyens W, Berneman ZN. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost 2002; 28:111-131.
4. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetic and hemostatic effect of different factor VIII/von Willebrand factor concentrates in vonWillebrand disease type III. Ann Hematol 1992; 65:253-259.
5. Fukui H, Nishino M, Terada S, Nishikubo T, Kinoshita S, Niinomi K, Yoshioka K. Hemostatic effect of a heat-treated factor VIII concentrate (Haemate-P) in von Willebrand''s disease. Blut 1988; 56:171-178.
6. Ivy AC, Nelson D, Bucher G. The standardization of certain factors in the cutaneous 'venostasis' bleeding time technique. J Lab Clin Med 1941; 84:160-174.
7. Cejka J. Enzyme immunoassay for FVIII-related antigen. Clin Chem 1984; 28:1356-1358.
8. MacFarlane DF, Stibbe J, Kirby EP. A method for assaying von Willebrand factor (ristocetine cofactor). Thromb Diath Haemorrhag 1975; 34:306-308.
9. Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand factor antigen to collagen. Thromb Res 1986; 43:303-311.
10. Brosstadt F, Kjonneksen I, Ronning B, Stormorken H. Visualisation of von Willebrand factor multimers by enzyme-conjugated secondary antibodies. Thromb Haemost 1986; 55:276-278.
11. Budde U, Drewke E, Mainusch K, Schneppenheim R. Laboratory diagnosis of congenital von Willebrand disease. Semin Thromb Hemost 2002; 28:173-189.
12. Mannucci PM. Recommended protocol for the study of ex vivo biological effects of virus-inactivated plasma concentrates with von Willebrand disease. Thromb Haemost 1992; 68:84-88.
13. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero R. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79:3130-3137.
14. Björkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokintics of factor VIII in humans. Clin Pharmacokinet 1992; 22:385-395.
15. Favaloro EJ. Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey. Semin Thromb Hemost 2002; 28:191-202.
16. Mannucci PM, Federici A. Management of inherited von Willebrand disease. Ballière's Clin Haematol 2001; 14:455-462.
17. Lillicrap D, Poon M-C, Walker I, Xie F, Schwartz BA, and the members of the Association of HemophiliaClinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristoocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87:224-230.
18. Mannucci PM, Chediak J, Bymes W, Ledford J, Ewenstein BM, Retzios AD, et al, and the Alphanate Study Group Treatment of von Willebrand disease with high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99:450-456.
19. Mannucci PM. Venous thrombosis in von Willebrand disease. Thromb Haemost 2002; 88:378-379.
20. Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002; 88:378-379.